Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTSGC-A24 Vaccine in Advanced Gastric Cancer
NCT01227772Phase 2Unknown
- Sponsor
- National University Hospital
- Start
- Nov 2010
- Primary completion
- Nov 2016
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 2, open-label trial of OTSGC-A24 in gastric cancer (GC) (3 cohorts), sponsored by National University Hospital. Primary endpoints: Safety of OTSGC-A24 at 4 weeks and Optimal dosing schedule at 1 year. Status: unknown.
02
Drugs
OTSGC-A24
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT01227772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01227772.